ClinicalTrials.gg
Active, not recruitingNCT07280377GOBLETUpdated May 19, 2026

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

A Phase 1/2 interventional study of Pelareorep and Atezolizumab in Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified and Pancreatic Cancer Metastatic, sponsored by Oncolytics Biotech. Active, not recruiting at 15 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Oncolytics Biotech · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Oct 2021, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Anus Neoplasms with a site in Germany — 3 open to participants now, 6 under way, none of them phase 3. Anus Neoplasms · Germany.

Planned enrollment
5th of 10
122 · median 120
Started
2021
the only one that year
Phase 1/2
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Oncolytics Biotech

Among the 11 studies in Anus Neoplasms with a site in Germany, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 1/2, and was the 11th registered.

Anus Neoplasms

298 studies on the registry are indexed under Anus Neoplasms; 75 are open to participants now.

Browse Anus Neoplasms studies →

Open to participants now

3 of the 11 studies in Anus Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 57 Anus Neoplasms studies recruiting now, 46 (81%) set no upper age limit and 7 (12%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Anus Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate [ORR; Cohorts 1,2, 4,and 5] and disease control rate [DCR; Cohort 3]) in patients with advanced or metastatic gastrointestinal (GI) tumors. Cohorts 1-4 are not randomized; however, Cohort 5 is comprised of two treatment arms to which patients are randomized in a 1:1 ratio.

Read the detailed description

The overall aim is to assess safety, predictive biomarkers, and preliminary efficacy as assessed by tumor response criteria at week 16 for cohorts1, 2, 3, and 4, and best overall response rate and OS in Cohort 5. If a cohort shows a promising ORR in Stage 1 of the Simon two-stage design, that cohort may be expanded to enroll additional patients (up to 50 patients in Cohorts 1 and 3 , up to 28 patients in Cohort 4, and up to 64 patients in Cohort 5) in an extension phase per predetermined statistical conditions. In addition, either or both arms of Cohort 5 may expand if the data collected in Stage 1 suggest that expansion may help in assessing the potential survival benefit of the investigational therapy(ies). In this study, we hypothesize that treatment with pelareorep will prime the tumor microenvironment (TME) for checkpoint blockade therapy, thereby increasing PD-L1 expression and the number of new T cell clones within the tumor, both of which are associated with increased response to checkpoint blockade.

03

Conditions studied

  • Anal Cancer Metastatic
  • Squamous Cell Carcinoma of the Anus Stage Unspecified
  • Pancreatic Cancer Metastatic
  • Unresectable Pancreatic Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Cohorts 1-5 Inclusion Criteria:

  • performance status of 0 or 1
  • Have per v1.1
  • Patients must have adequate hematological, renal, and hepatic function
  • Have recovered to ≤grade 1 or baseline for all adverse events (AEs) due to previous therapies or surgeries.
  • For female patients of and male patients with partners of childbearing potential, agreement to use a highly-effective form(s) of and to continue its use for 6 months after the last dose of study drug.

Exclusion Criteria:

  • Undergone systemic chemotherapy, radiotherapy, or surgery, \<4 weeks before study treatment.
  • Received previous treatment with
  • Uncontrolled or severe cardiac disease
  • Active, uncontrolled infections
  • Symptomatic
  • Interstitial lung disease with symptoms or signs of activity.
  • disease that has required systemic treatment in the past 2 years with disease modifying agents, , or drugs.
  • A seizure disorder that requires pharmacotherapy.
  • Known to any of the study drugs, study drug classes, or in the formulation.
  • A non-healing wound, non-healing ulcer, or non-healing bone fracture within 4 weeks prior to the start of study drug.
  • Women who are pregnant or breastfeeding.
  • A diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy
  • Any vaccine within 28 days prior to first treatment or during the first cycle of study treatment.

Exclusion Criteria:

  • In Cohort 1, 2, 3, 4: less than 3 months
  • In Cohort 1, 2, 3: known active (HBV) or (HCV) infection that requires anti-viral treatment.
  • In Cohort 4: Prior infection if the CD4+ T cell is \<300 cells/µl
  • In Cohort 5: Known low or absent dihydropyrimidine dehydrogenase (DPD) activity.
  • In Cohort 5: Known .
  • In Cohort 5: History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Metastatic Pancreatic Cancer 1L

    Patients with first-line (1L) locally advanced/metastatic unresectable pancreatic ductal adenocarcinoma (PDAC): Pelareorep and atezolizumab added to gemcitabine and nab-paclitaxel

    Drug: Pelareorep · Drug: Atezolizumab · Drug: Gemcitabine and nab-paclitaxel

  • Experimental
    Cohort 2: Metastatic Colorectal Cancer 1L (MSI-H/dMMR)

    Patients with 1L metastatic colorectal cancer (mCRC), limited to microsatellite instability-high (MSIH) or mismatch repair deficient (dMMR) tumors: Pelareorep and atezolizumab

    Drug: Pelareorep · Drug: Atezolizumab

  • Experimental
    Cohort 3: Metastatic Colorectal Cancer 3L

    Patients with third-line (3L) mCRC independent of microsatellite instability (MSI)/dMMR status: Pelareorep and atezolizumab added to trifluridine/tipiracil

    Drug: Pelareorep · Drug: Atezolizumab · Drug: Trifluridine Tipiracil

  • Experimental
    Cohort 4: Metastatic Unresectable Anal Cancer >/=2L

    Patients with \>/= 2L locally advanced/metastatic unresectable squamous cell carcinoma of the anal canal (SCCA) of viral or non-viral origin after prior systemic chemotherapy: Pelareorep and atezolizumab

    Drug: Pelareorep · Drug: Atezolizumab

  • Experimental
    Cohort 5: Metastatic PDAC 1L

    Patients with 1L metastatic PDAC: Pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab

    Drug: Pelareorep · Drug: Atezolizumab · Drug: mFOLFIRINOX Treatment Regimen

Interventions

  • Pelareorep 4.5 x 10\^10 TCID50 via 1-hour IV infusion

  • Atezolizumab 840 mg IV infusion

    Also known as: Tecentriq

  • DrugGemcitabine and nab-paclitaxel

    Gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2)

    Also known as: Gemzar, Abraxane

  • DrugTrifluridine Tipiracil

    Trifluridine/tipiracil administered at a 35 mg/m2 dose orally twice daily

    Also known as: Lonsurf

  • DrugmFOLFIRINOX Treatment Regimen

    Drug pages: Fluorouracil · Leucovorin · Irinotecan · Oxaliplatin

    mFOLFIRINOX- IV oxaliplatin 85 mg/m2; IV leucovorin 400 mg/m2; IV irinotecan 150 mg/m2; 5-FU 2400 mg/m2 by 46-hour infusion, per local standard of care

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5

    Proportion of patients with complete response \[CR\], partial response \[PR\] assessed by the investigators and/or central reader according to RECIST v1.1

    Time frame: At week 16 (within each cohort)

  2. Disease Control Rate (DCR) - Cohort 3

    DCR (complete response \[CR\], partial response \[PR\], and stable disease \[SD\]) assessed by the investigators according to RECIST v 1.1.

    Time frame: at week 16

  3. Overall Survival (OS) - Cohort 5

    OS is defined as the time from date of first treatment to death from any cause

    Time frame: Cohort 5: From the date of randomization through long term follow up at 2 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time from the first dose date of study treatment to the date of investigator-determined objective progression (according to RECIST 1.1) or death from any cause, whichever occurs first.

    Time frame: From initiation of treatment to objective progression or death from any cause, whichever occurs first, up to two years

  2. Duration of Response (DOR)

    Time from documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death.

    Time frame: From initiation of treatment to disease progression or death from any cause, whichever occurs first, up to two years

  3. Disease Control Rate (DCR)

    Overall DCR, defined as the number of patients with a best overall response of CR, PR, or SD according to RECIST v. 1.1.

    Time frame: From initiation of treatment to disease progression or death from any cause, whichever occurs first, up to two years

  4. Overall Response Rate (ORR) - Cohort 1-4

    ORR, defined as the percentage of patients with a best overall response of complete response \[CR\] or partial response \[PR\] according to RECIST v 1.1, and confirmed ORR, defined as the percentage of patients with a CR or PR at two or more consecutive evaluation timepoints.

    Time frame: From initiation of treatment to disease progression or death from any cause, whichever occurs first, up to two years

  5. Overall Survival (OS) - Cohort 1-4

    OS defined as the time from date of first treatment to death from any cause

    Time frame: From the date of randomization through long term follow up at 3 years

07

Study locations

15 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Jul 2027, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 12, 2025
StartActual
Oct 27, 2021
Primary completionEst.
Jul 30, 2027
CompletionEst.
Dec 31, 2028
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07280377
Lead sponsor
Oncolytics Biotech
Collaborators
Crolll Gmbh, AIO-Studien-gGmbH
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Oct 27, 2021
Primary completion
Jul 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelareorep

Start the discussion